SCHEMBL6860944

SCHEMBL6860944

NCC1CCc2cc(C(=O)O)ccc2O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
ITGB3 P05106 2/20 0.48
ITGA2B P08514 2/20 0.48
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 2/20 0.41
SRD5A1 P18405 2/20 0.40
SRD5A2 P31213 2/20 0.40
RXRA P19793 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
FFAR4 Q5NUL3 2/20 0.38
POLB P06746 1/20 0.38
BLM P54132 1/20 0.38
GRM1 Q13255 1/20 0.38
FFAR1 O14842 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
CA2 P00918 2/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7492566 0.99 TDP1 (0.50) TDP1ITGB3ITGA2BALDH1A1MAPK1
SCHEMBL10506385 0.87 TDP1 (0.52) TDP1ITGB3ITGA2BALDH1A1MAPK1
SCHEMBL22663014 0.86 TDP1 (0.55) TDP1ITGB3ITGA2BALDH1A1MAPK1
SCHEMBL27280906 0.82 TDP1 (0.48) TDP1ITGB3ITGA2B
SCHEMBL10366696 0.82 TDP1 (0.48) TDP1ITGB3ITGA2B
SCHEMBL22978820 0.82 TDP1 (0.51) TDP1ITGB3ITGA2BALDH1A1RXRA
SCHEMBL27283082 0.82 TDP1 (0.48) TDP1ITGB3ITGA2B
SCHEMBL6863568 0.82 CYP4F2 (0.47) ITGB3ITGA2BALDH1A1MAPK1SRD5A1
Hydrochloric Acid SCHEMBL6863563 0.81 CYP4F2 (0.46) ITGB3ITGA2BALDH1A1MAPK1SRD5A1
SCHEMBL6855344 0.81 ITGB3 (0.48) TDP1ITGB3ITGA2BALDH1A1SRD5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797714-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION BAYER PHARMACEUTICALS CORPORATION 2004-09-28 US disclosed
US-6469031-B1 USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS BAYER CORPORATION 2002-10-22 US disclosed